A drug called bepirovirsen has shown promising results in clinical trials for chronic hepatitis B, a disease that affects roughly 300 million people worldwide. In testing, about one in five patients treated with the drug were able to stop medication and maintain virus-free blood test results for six months afterward. This outcome, called a "functional cure," would represent a significant step forward for hepatitis B treatment.

To understand why this matters, it helps to know what "functional cure" actually means. It is not the same as eradication — the virus is not completely removed from the body. Instead, it means the virus becomes undetectable in blood tests and stays inactive in the liver, even after treatment stops. Current standard hepatitis B medications suppress the virus, but patients must take them indefinitely. A functional cure, by contrast, would allow patients to eventually stop treatment altogether.

For comparison, an older hepatitis B drug called interferon-alpha has been available for decades and can achieve this undetectable state in roughly 10 percent of patients. However, it is often too difficult to tolerate due to its side effects. If bepirovirsen can double that success rate with fewer side effects, it would change how doctors and patients think about hepatitis B treatment.

How the New Drug Works

Bepirovirsen is an antisense oligonucleotide — a relatively new class of medicine that targets viral genetic material to shut down the production of harmful proteins. For hepatitis B specifically, it silences the virus's ability to make the surface marker that appears in blood tests, a protein called HBsAg. Current standard medications suppress the virus but do not eliminate this protein from blood. That distinction is important: removing HBsAg entirely is one of the hallmarks of a functional cure.

Competitors Are Close Behind

Bepirovirsen is not the only contender in the race to find a hepatitis B functional cure. AusperBio, a company in China, has advanced another experimental drug called AHB-137 into later-stage testing. China bears a disproportionate share of the global hepatitis B burden, and there is significant scientific and commercial effort to develop a locally produced cure.

A more advanced approach is underway in combination therapy. Researchers at Brii Biosciences, partnering with Vir Biotechnology and VBI Vaccines, are testing a pairing of two drugs: one that suppresses the virus directly, and another that is designed to reawaken the immune system's ability to recognize and fight it. The rationale is straightforward: chronic hepatitis B exhausts the immune system, so simply driving the virus down may not be enough. You also need to restore the body's own defenses.

Further back in development, researchers have identified a new compound called KC13-M2G2 that shows promise in laboratory and animal studies. It shuts down multiple viral proteins simultaneously without harming healthy cells. Animal studies do not always translate to human results, and this compound is still years away from human testing, but the design suggests researchers are specifically optimizing for the functional-cure goal.

Why One Drug Alone Might Not Be Enough

The prevailing view among hepatitis B researchers is that a true functional cure will require combination therapy — multiple drugs working in different ways simultaneously. This mirrors how the field eventually cracked other difficult viral infections. HIV treatment was transformed by combining three or more drugs that attacked the virus at different steps; hepatitis C was functionally cured in the vast majority of patients once researchers moved from single drugs to combinations.

The challenge with hepatitis B is unique. The virus has an unusual way of persisting in liver cells that creates a deeper reservoir than either HIV or hepatitis C. This means researchers cannot simply copy the HIV or hepatitis C playbook, though the broad principle — applying simultaneous pressure across multiple fronts — still holds.

The broader context here: the components needed for a working combination are actually coming together rather than falling apart. Several distinct types of drugs are advancing in parallel — viral suppressors, immune boosters, and others — in a way that simply did not happen five or ten years ago. The convergence of these different tool classes is what makes researchers cautiously optimistic that a workable combination might be within reach within the next few years.

A Nearby Success Story

The FDA recently approved the first-ever treatment for hepatitis delta, a related liver infection that co-occurs with hepatitis B and makes the disease much worse. Hepatitis delta had no approved treatment until now, yet the agency cleared this new drug based on solid evidence of benefit. That regulatory precedent suggests that novel approaches to hard-to-treat liver viruses can earn FDA approval when clinical data are strong enough.

Where We Stand

As of mid-2026, bepirovirsen is the furthest along, with human trial results showing a meaningful improvement over older treatments. The combination approaches are in mid-stage testing and their results will be critical — they will show whether or not adding immune restoration to viral suppression actually makes a practical difference. A Chinese-developed competitor is now also in late-stage testing, adding a competitive dynamic. Earlier research has not stopped; new compounds continue to emerge from the laboratory.

A complete cure for hepatitis B that works for most patients does not yet exist. What does exist is a coordinated research effort with a clear goal and multiple paths forward. The real work now lies in running the later-stage trials, getting drugs through regulatory approval, and — most importantly — making sure that whatever reaches the market actually gets to the hundreds of millions of people in Africa, Southeast Asia, and elsewhere who live with this disease.

The biggest question is not whether the science will work. It is whether treatment will reach the patients who need it most.